R1 RCM Inc

R1 RCM — Q1 2021 Earnings Presentation

13 slides from R1 RCM's earnings presentation, May 4, 2021

  1. Slide 1: First Quarter 2021 Results Conference Call

    First Quarter 2021 Results Conference Call May 4, 2021 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures

    2 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not

  3. Slide 3: Q1 Financial Highlights and Commercial Update

    3 Q1 Financial Highlights and Commercial Update First Quarter 2021 Results ▪ Revenue of $342.6 million, up $22.1 million or 6.9%1 compared to the same period last year ▪ GAAP net income of $25.8 million, up $7.6 million or 41.8% compared to the same period last year ▪ Adjusted EBITDA of $80.4 millio

  4. Slide 4: VisitPay Transaction Highlights and Rationale

    4 VisitPay Transaction Highlights and Rationale Accretive to Growth ▪ Accelerates revenue and EBITDA growth trajectory through additional high margin SaaS offering Significant Synergies ▪ Compelling opportunities from increased digital adoption and improved patient yield ▪ Potential for meaningful c

  5. Slide 5: VisitPay Overview: Enterprise Patient Payment Platform

    5 VisitPay Overview: Enterprise Patient Payment Platform Single solution from intake to back-end billing creates a unified experience for the patient and staff Consolidated household billing across all acute and ambulatory systems, with EOB displayed at visit level; HSA and other insurance informati

  6. Slide 6: Patient Experience (PX) Platform: Market-Leading Capabilities

    6 Book Intuitive Scheduler ▪ Order & referrals integrated from the start ▪ Patients and providers book in real-time based on true capacity ▪ Built-in proprietary clinical & administrative rules & logic Patient Payments ▪ Seamless payment and billing experience across settings of care ▪ Intuitive pay

  7. Slide 7: Strategic Expansion and Extension of Ascension Agreement

    7 ▪ Expansion of agreement is across three categories: 1. Comprehensive deployment of PX across acute and ambulatory environments 2. Expansion of scheduling scope and certain patient-facing services through our global delivery centers 3. Broader application of technology and use cases for automating

  8. Slide 8: 1Q'21 Non-GAAP Results – Q/Q and Y/Y Comparison

    8 1Q'21 Non-GAAP Results – Q/Q and Y/Y Comparison ($ in millions) 1Q'21 4Q'20 1Q'20 Key Change Driver(s) Revenue $342.6 $328.4 $320.5 ▪ Q/Q: Continued recovery in patient volumes, higher incentive fees ▪ Y/Y: Contribution from SCI, higher incentive fees, and new customers onboarded in 2021 Adjusted

  9. Slide 9: Additional Commentary

    9 Additional Commentary ▪ Up from $379.8 million as of 12/31/20, driven by - Use of cash for $105 million payment for the conversion of preferred shares to common - Capex of $9.6 million ▪ $130+ million in liquidity as of 3/31/21 ▪ Seeking to refinance senior credit facilities in conjunction with Vi

  10. Slide 10: Appendix: Reconciliation of GAAP to Non-GAAP Financials

    10 Appendix Reconciliation of GAAP to Non-GAAP Financials

  11. Slide 11: Use of Non-GAAP Financial Measures

    11 Use of Non-GAAP Financial Measures ▪ In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial performance

  12. Slide 12: Reconciliation of GAAP to Non-GAAP Financials

    12 Reconciliation of GAAP to Non-GAAP Financials Note (1): Other expenses are comprised of reorganization-related costs, strategic initiatives costs, and certain other costs. Three Months Ended March 31, Three Months Ended December 31, 2021 2020 2020 Net income $ 25.8 $ 18.2 $ 78.6 Net interest expe

  13. Slide 13: Reconciliation of GAAP to Non-GAAP Financials

    13 Reconciliation of GAAP to Non-GAAP Financials Reconciliation of GAAP Operating Income Guidance to Non-GAAP Adjusted EBITDA Guidance 2021 GAAP Operating Income Guidance $135-155 Plus: Depreciation and amortization expense $70-80 Share-based compensation expense $55-60 Strategic initiatives, severa

R1 RCM — Q1 2021 Earnings Presentation on 6ix